In the past 3 years, altered expression of the HEF1/CAS-L/ NEDD9 scaffolding protein has emerged as contributing to cancer metastasis in multiple cancer types. However, whereas some studies have identified elevated NEDD9 expression as prometastatic, other work has suggested a negative role in tumor progression. We here show that the Nedd9-null genetic background significantly limits mammary tumor initiation in the MMTV-polyoma virus middle T genetic model. Action of NEDD9 is tumor cell intrinsic, with immune cell infiltration, stroma, and angiogenesis unaffected. The majority of the late-appearing mammary tumors of MMTV-polyoma virus middle T;Nedd9 À/À mice are characterized by depressed activation of proteins including AKT, Src, FAK, and extracellular signal-regulated kinase, emphasizing an important role of NEDD9 as a scaffolding protein for these prooncogenic proteins. Analysis of cells derived from primary Nedd9 +/+ and Nedd9 À/À tumors showed persistently reduced FAK activation, attachment, and migration, consistent with a role for NEDD9 activation of FAK in promoting tumor aggressiveness. This study provides the first in vivo evidence of a role for NEDD9 in breast cancer progression and suggests that NEDD9 expression may provide a biomarker for tumor aggressiveness.
Introduction
Human breast cancer is a heterogeneous disease characterized by variable response to treatment and differences in prognosis (1) , with mortality commonly linked to the existence of distant metastases on diagnosis (2) . It is well established that primary lesions inducing the aberrant expression or activity of proteins such as the transmembrane receptor ErbB2/HER-2, the estrogen receptor, and the classic tumor suppressors such as p53 contribute to breast cancer incidence and progression. More recently, altered expression or activation of additional proteins such as FAK (3), AKT (4), ShcA (5), integrins (6) , and other proteins operating in signaling networks associated with cell survival and metastasis have also been implicated in modulating breast cancer disease course. Although, in some cases, these proteins are mutationally activated; in other cases, activity is enhanced without clearly responsible genetic lesions. In these cases, it is likely that the activity of core cancer-promoting signaling proteins is induced by changes in as yet poorly defined signaling partners, which augment their function to promote transformation.
The HEF1 (7)/CAS-L (8)/NEDD9 noncatalytic scaffolding protein is best known for its roles in coordinating the FAK and Src signaling cascades relevant to integrin dependent adhesion, migration, and survival (9) (10) (11) (12) . Recently, functional interactions between NEDD9 and Rac have been shown to be necessary for mesenchymal movement in melanoma cell motility and invasion (13) . DNA amplification or transcriptional up-regulation of the NEDD9 gene, leading to elevated expression of the NEDD9 protein, has been reported as a potent regulator of cancer progression, invasion, and metastasis in melanoma (14) and glioblastoma (15) and linked to metastasis of LKB1 À/À lung tumors (16) . As such, NEDD9 expression changes have been proposed as biomarkers for tumor aggressiveness. NEDD9 is abundantly expressed in many breast cancer cell lines (17) and hyperphosphorylation associated with activation of NEDD9 has been detected in phosphoproteome analysis of heregulin-stimulated ErbB2-positive breast adenocarcinoma MCF7 cells (18) . However, an in vivo role for NEDD9 in breast cancer has not been established. Although NEDD9 overexpression clearly promotes migration and invasion in MCF7 cells (12) and other cancer cell lines (14, 15) , small interfering RNA depletion of NEDD9 identified this gene as an inhibitor of migration in untransformed MCF10A breast epithelial cells (19) . Further, an independent study identified down-regulation rather than upregulation of Nedd9 as part of a transcriptional signature associated with enhanced metastasis to the lung in a transforming growth factor-h (TGF-h)-associated mammary cancer model (20) . These conflicting results raise the possibility that, at least in some cell types, it is loss of Nedd9 rather than overexpression of Nedd9 is tumor-promoting, comparable with the complex cell type-specific activity of proteins such as antigen-presenting cells, which can act either as an oncogene or tumor suppressor (21) .
The recent development of a viable, fertile Nedd9 knockout strain (22) provided the opportunity to directly evaluate the role of Nedd9 in mammary cancer initiation and progression. The polyoma virus middle T (PyVmT) antigen induces tumorigenesis based on large part on its binding and activation of the proteins Shc, Src, and phosphoinositide 3-kinase, which are central effectors of ErbB2/HER-2 (reviewed in ref. 23 ). Detailed pathologic analysis of PyVmT tumors indicates progression from premalignant to highly malignant stages is very similar to that seen in human breast tumors (24) , and a large-scale microarray profiling study has confirmed that cancers arising from overexpression of PyVmT, ErbB2/HER-2, and Ras showed tightly clustered gene expression profiles that were distinct from those associated with Myc-initiated or SV40 T antigen-initiated tumors, further confirming relevance to human disease (25) . In this study, we have used the MMTVPyVmT oncogenic model to compare mammary tumor progression in Nedd9 wild-type versus null genetic backgrounds. Our data indicate that lack of Nedd9 significantly limits tumor incidence and oncogenic signaling in mammary tumors. Surprisingly, mammary tumor growth in Nedd9-null mice show differences from Nedd9 wild-type mice from the time premalignant lesions are first detectable, in contrast to previous suggestions of a role for this protein in metastasis, and also show that these differences are linked to reduced activation of multiple signaling pathways linked to tumor cell growth and invasion in Nedd9-null mice.
Materials and Methods
Mouse strains, handling, and measurement of tumors. All experiments involving mice were preapproved by the Fox Chase Cancer Center Institutional Animal Care and Use Committee. MMTV-PyVmT mice (26) of the 634Mul/J subline were purchased from The Jackson Laboratory. Homozygous C57BL/6 Nedd9 À/À females (22) were crossed with MMTV-PyVmT males. Female Nedd9 +/À offspring were mated with Nedd9 +/À ; PyVmT-positive males to generate virgin female siblings for analysis.
Tumor growth assessment. Mice were palpated twice weekly to assess mammary tumor onset. Tumor volume was calculated following caliper measurement as width Â length Â 0.4. Mice were euthanized by methoxyfluorane (Metofane) inhalation when the longest dimension of the largest tumor reached 2 cm or if mice exhibited signs of illness or distress. The largest tumor and lungs were excised, divided, and processed for Western analysis and pathology. Pathology specimens were fixed overnight in paraformaldehyde, paraffin-embedded, sectioned, and analyzed by H&E staining (Sigma-Aldrich). Tumor sections were immunostained with antibodies to Mac2 (Cedarlane), B220-CD45R (Pharmingen), CD31, CD3, and Ki-67 (DAKO). Images were acquired using a Nikon Eclipse E600 microscope. Lung metastases were expressed as number of metastases per square millimeter of lung cross-section using Image Pro-Plus (Media Cybernetics). All analyses were done by a board-certified pathologist (A.K-S.) blinded to sample identity.
For Fig. 1A , we used Kaplan-Meier curves with log-rank tests. For Fig. 1B , we used semiparametric regression (27) . For Fig. 1C , we used Poisson regression estimated by generalized estimating equations assuming a Markov correlation structure (28) and including age in the model via restricted cubic splines (29) and interacting it with Nedd9 group. For Supplementary Fig. S1 and Fig. 5C and D, we used similar generalized estimating equations-estimated linear regressions with appropriate correlation structures. For Supplementary Table S1 and Figs. 1D, 3B and C, 5B, and 6B, we used Wilcoxon rank-sum tests. For Fig. 4D , we fit simple linear regressions of age with ordinal biomarker covariates (low, medium, high, and wild-type). Robust SEs were used for regressions. Error bars in figures represent F1 SE. Early lesions. MMTV-PyVmT;Nedd9 À/À and MMTV-PyVmT;Nedd9 . For whole-mount analysis, excised thoracic mammary glands attached to glass slides were treated with acetone overnight and then immersed in 70% ethanol for 1 h, washed with distilled water, and put in alum carmine solution (Fisher Scientific) overnight. Sections were destained in increasing ratios of ethanol to distilled water for 30 min, treated with Histoclear overnight, and photographed.
Western analysis of tumor lysates. Tumor sections histologically confirmed to contain >90% tumor tissue were harvested, homogenized, and lysed in PBS-TDS buffer (1Â PBS, 1% Triton X-100, 0.1% SDS, 20% glycerol) containing complete protease and phosphatase inhibitor cocktail (Roche Diagnostic). Whole-cell lysates from the human breast cancer cell line MCF7 were used as positive loading controls. Primary antibodies used recognized NEDD9 (2G9; ref. 30 , and ERK1/2 and AKT (Cell Signaling), and h-actin (Sigma). Secondary horseradish peroxidaseconjugated antibodies were from Amersham Biosciences. Proteins were visualized using the West-Pico system (Pierce). Image analysis was done using NIH ImageJ (NIH), with signal intensity normalized to h-actin.
Derivation of cells. Tumors were dissected, rinsed with PBS and minced, and then treated with 0.2% collagenase for 2 h at 37jC. Cells were washed several times with serum-free DMEM and finally with low-calcium medium supplemented with 5% horse serum. Tissues kept in low-calcium medium were transferred to T-25 flasks coated with 0.1% gelatin and incubated in a 37jC incubator overnight. The next day, supernatants containing floating cells were transferred and seeded into new flasks, and maintained with regular medium changes until confluency, to prevent fibroblast growth. Fibroblast-free cell populations were derived typically after 6 to 8 weeks. In vitro proliferation was measured by seeding f1 Â 10 5 cells on 0.1% gelatin-coated T25 flasks. At specific time points, cells were trypsinized and counted using trypan blue exclusion analysis. All analyses used cells passaged <6 times.
Cell spreading, migration, proliferation, and anoikis. Cells were fixed in 4% paraformaldehyde, permeabilized in 0.2% Triton X-100, and blocked with 3% bovine serum albumin in PBS before incubation with antibodies. Epifluorescence was measured using an inverted Nikon TE300 microscope, with 12-bit images acquired using a Spot RT monochrome camera (Diagnostic Instruments). To measure cell attachment, a-paxillin monoclonal antibody was used to outline cells, and cell area measurements were made using MetaMorph or MetaVue software (Molecular Devices, Universal Imaging) to score pixels within cell perimeters. Cell motility was monitored with a Nikon TE300 microscope using 10Â NA 0.25 Plan A objective, and images were collected with a CCD video camera (Roper Scientific) at 20-min intervals over a 12-h period and then digitized and stored as image stacks using MetaMorph. For wound-healing assays, cell monolayers were wounded with pipette tips; cells were incubated at 37jC on the stage of a Nikon Eclipse E800 inverted microscope (Carl Zeiss), whereas images were acquired for 12 h with a Quantix-cooled CCD camera (Roper Scientific). For anoikis assays, cells were grown on poly-HEMA (Sigma-Aldrich), and apoptosis was measured by Annexin V staining using a kit from Guava Technologies. Lysates were prepared using standard procedures. Caspase-3 antibodies were obtained from Cell Signaling.
Results

Nedd9
À/À status limits early tumor development in MMTVPyVmT-induced mammary tumors. We compared the incidence and latency of mammary tumor appearance in Nedd9 À/À or Nedd9 +/+ mice in the presence or absence of the MMTV-PyVmT transgene (Fig. 1) . No animals lacking the MMTV-PyVmT transgene developed mammary tumors in a study group maintained until age 1 year. However, Nedd9 À/À status significantly limited multiple parameters of MMTV-PyVmT-induced early mammary tumor development and progression, including average age at initial detection of tumors (62 days for Nedd9 À/À versus 51 days postnatal for Nedd9 +/+ ; Fig. 1A ). There was also a reduction in total tumor burden (Fig. 1B) , number of independent tumors (Fig. 1C) , and growth rate of the largest single tumor (Supplementary Fig. S1 ). Nedd9 À/À status also was associated with a trend toward fewer lung metastases (Fig. 1D) . However, this was not statistically significant given the very low overall numbers of metastases detectable at the time the volume of the primary mammary tumors necessitated euthanasia.
À/À status does not affect normal mammary gland development but delays tumor formation. The limiting effect of loss of Nedd9 on initial mammary tumor development might reflect intrinsic differences in mammary gland development that limit tumor precursor cell populations or differences in tumor development in a comparable mammary gland microenvironment. Comparison of whole-mount and paraffin-embedded specimens of mammary glands from adolescent, young adult, pregnant, lactating, and postinvolution mice indicated no detectable differences between Nedd9 À/À and Nedd9 +/+ animals (Supplementary Fig. S2 ; data not shown). However, MMTV-PyVmT-induced neoplastic lesions appeared earlier in Nedd9 +/+ mice ( Fig. 2A) , and fewer independent primary lesions were observed in Nedd9 À/À animals at both 4-and 6-week time points. Ki-67 staining indicated a lower percentage of proliferating cells in the mammary tumors in MMTVPyVmT;Nedd9 À/À versus MMTV-PyVmT;Nedd9 +/+ mice at both ages 4 and 6 weeks ( Fig. 2A and B) . Histopathologic analysis indicated no qualitative morphologic differences between the comparably staged early mammary tumors of MMTV-PyVmT;Nedd9
À/À and MMTVPyVmT;Nedd9 +/+ mice, bolstering the idea that the primary difference at the early time point predominantly reflected differences in growth rate. Finally, analysis of Ki-67 staining in tumors at the time of euthanasia indicated that overall differences in proliferation seen in early lesions were no longer apparent (Fig. 2C) . Reduced tumor growth in Nedd9 À/À mice reflects tumorintrinsic action. NEDD9 has been implicated in endothelial cell signaling (31) and Nedd9 À/À mice have specific defects in immune system maturation and migration (22) , raising the possibility that consequences of loss of Nedd9 on tumor growth might in part reflect effects of the microenvironment. However, immunohistochemical staining for CD31 to visualize vascularization of mammary tumors in MMTV-PyVmT;Nedd9 +/+ versus MMTV-PyVmT;Nedd9 À/À mice indicated no significant differences (Fig. 3A and B) . Immunohistochemical staining for markers of T cells (CD3), B cells (CD45R), and macrophages (Mac2) indicated no Nedd9-dependent difference in the infiltration of these cells into tumors ( Fig. 3C and D) . Together, these data supported a tumor-intrinsic effect of Nedd9 Fig. 4B and C) .
The set of tumors with reduced FAK activation overlapped almost entirely with the set of tumors with reduced Src activation, reflecting the interdependence of the two activation processes. Total expression levels of FAK and Src were not affected by Nedd9 status.
NEDD9 has partially overlapping function with its paralogue p130
Cas /BCAR1 (32), which is also expressed in mammary cells, and can both dimerize with NEDD9 and sustain activation of FAK and Src (7, 33) . Whereas variance in p130
Cas levels as a consequence of Nedd9 deletion might explain the heterogeneous activation of FAK and Src in PyVmT;Nedd9 À/À tumors (Fig. 4B ), p130 Cas levels were consistent in all tumor lysates regardless of Nedd9 genotype.
In addition to their roles in cell migration and invasion, FAK and Src phosphorylate and activate the ShcA adaptor, an upstream activator of the Ras pathway (34) . Hence, NEDD9 could potentially be required for activation of Shc-dependent signaling proteins that influence proliferation (Fig. 4A) , relevant to the reduced proliferation phenotype of the early Nedd9 À/À lesions (Fig. 2) (Fig. 4B) . The subset of Nedd9 À/À tumors with reduced FAK or Src activation overlapped very significantly with the set of tumors with reduced Shc phosphorylation and also correlated well with the set of tumors with reduced AKT phosphorylation. Given these results and the known close connection between FAK and Shc, we investigated whether NEDD9 associated with Shc and indeed identified robust coimmunoprecipitation of these proteins in vivo, supporting a direct link relevant to control of cell proliferation ( Supplementary Fig. S3 ). Some overlap was also seen between the tumor sets lacking FAK, Src, and ERK1/2 activation although not to the same degree as with Shc or AKT; this likely reflects the many diverse cellular signaling pathways contributing to ERK activation. Finally, for both phospho-FAK-Y 397 and phospho-ERK-T 202 /-Y 204 , we confirmed that the NEDD9-dependent differences we observed in the tumor cell lysates were also detectable by immunohistochemistry specifically in tumor cells (Supplementary Fig. S4 ), in congruence with other data (Fig. 3) indicating that the action of Nedd9 was tumor-intrinsic.
Importantly, segregation of individual MMTV-PyVmT;Nedd9
À/À mice into groups characterized by low, intermediate, or high levels of activation of these proteins revealed significant trends in which low pathway activation correlated with later tumor onset (Fig. 4D) . Whereas the average latency until tumor appearance was 62 days for Nedd9 À/À versus 51 days for Nedd9 +/+ animals, latency was delayed until z66 days for the group of tumors with the lowest signaling pathway activation. These results strongly supported the idea that activation of these NEDD9-dependent pathways was relevant to the requirement of NEDD9 for efficient tumor development.
Nedd9 À/À cell lines have reduced FAK activation, spreading, and migration but complex cell survival properties. Because of the central relation of FAK-NEDD9 interactions to NEDD9 affects multiple prooncogenic signaling cascades, we next assessed three independent MMTV-PyVmT;Nedd9 À/À -derived versus three MMTV-PyVmT;Nedd9 +/+ -derived tumor cell lines to determine whether failure to activate FAK was a persistent and functionally important in this physiologic context. Although both Nedd9 +/+ and Nedd9 À/À cells formed paxillin-positive focal adhesions (Fig. 5A ), these were morphologically distinct between the two cell types, with larger and more clustered focal adhesions (associated with reduced motility) seen in Nedd9 À/À cells. Strikingly, few of the focal adhesions in Nedd9 À/À cells were positive for activated phospho-FAK-Y 397 , whereas most of those observed in Nedd9 +/+ cell lines were phospho-FAK-Y 397 positive, confirming that FAK activation remained dependent on NEDD9 in cancer-derived cell lines.
In overexpression and small interfering RNA depletion models, NEDD9/FAK/Src interactions have been shown to regulate cell attachment, migration, and detachment-associated cell survival (anoikis; refs. 9, 10). Initial attachment of cells to fibronectin was very significantly reduced in Nedd9 À/À cell lines (Fig. 5B) . Further, two discrete cell migration assays revealed very significantly decreased rates of cell migration in Nedd9 À/À cells ( Fig. 5C and D), with many Nedd9 À/À cells showing little or no motility.
Further, growth of cell lines on poly-HEMA to prevent attachment was associated with earlier and enhanced appearance of the apoptotic markers Annexin V (Fig. 6A ) and cleaved caspase-3 ( littermates aged to 1 year, no animals showed signs of illness, and no spontaneous solid tumors were detected after complete autopsies and histopathologic studies of multiple tissues. Mammary tissue from 1-year-old animals was indistinguishable between animals with different Nedd9 genotypes (data not shown). Extensive literature suggests an important role for NEDD9 in signaling related to normal differentiation and function of cells in the hematopoietic system (8, 22, 37, 38 Table S1 ) and analysis of blood cells within tissues indicated subtle but statistically significant distortion in some cell populations in Nedd9 À/À versus Nedd9 +/+ mice (Supplementary Table S1 ; Supplementary Fig. S5B and C) . In particular, decreased B cells but increased macrophages were found in the peripheral blood and spleen of Nedd9 À/À in comparison with Nedd9 +/+ mice (Supplementary Table S1 ). This suggests that long-time imbalance of NEDD9-dependent signaling is sufficient either to trigger proinflammatory and/or preneoplastic changes in immune system cells or to bias clonal outgrowth of specific cell populations based on a defect in the immune system microenvironment. One possibility for the different dependence on NEDD9 in different tissues may be varying abundance of either specific NEDD9 paralogues (e.g., refs. 39, 40) or partner proteins, leading to different signaling outcomes.
Discussion
Our results reveal that NEDD9 is a cancer cell-intrinsic protein that contributes to mammary tumor development in the MMTVPyVmT mouse model. In reference to other genetic modifiers that have been tested in the MMTV-PyVmT model, the effect of Nedd9-null status is not as dramatic as that seen with deletion of its binding partner FAK (41) but comparable with or greater than that observed in mice null for the important breast cancer signaling proteins PAR1 (42), MEKK1 (43), CD44 (44) , and others. These results suggest that NEDD9 expression may be an important modulator of breast cancer incidence in humans.
Although our data are compatible with the prooncogenic role identified for NEDD9 overexpression in glioblastoma, melanoma, and lung cancers (14-16), they differ in important ways. In Figure 6 . NEDD9 status conditions anoikis responses. A, percent of cells positive for Annexin V after growth on poly-HEMA or on plastic. Average of three cell lines per genotype. Differences were statistically significant at 12 and 24 h (P < 0.002) but not at 48 h (P = 0.076) for poly-HEMA growth; a small difference was also seen in cells grown 48 h on plastic (P = 0.011). B, Western analysis of cells grown on poly-HEMA (top ) or on plastic for 48 h. Arrow, uncleaved caspase-3 (CASP3 ); asterisk, cleaved products. particular, lack of NEDD9 reduces proliferation from very early stages of tumor development, rather than acting at the point of invasion and metastasis, as suggested by other studies. This reduced rate of tumor onset likely reflects an important role for NEDD9 in maintaining activation not only of its direct partners, FAK and Src, but also the key Ras effectors AKT, ShcA, and ERK1/2. The striking correlation of the degree to which these pathways are activated with the time of tumor detection argues that supporting this activation is a critical early action of NEDD9. In this context, the novel interaction between NEDD9 and Shc we report here provides a direct means by which NEDD9 supports Ras/Raf pathway activation. Together with the fact that an earlier study has shown that NEDD9-dependent tumor promotion has been shown previously to be partly dependent on Ras/Raf pathway activation (14) , these data suggest that close coordination rather than strict unidirectional epistasis explains the relation of NEDD9 and Ras signaling in tumor growth.
Given our results, the opposite suggestion by Minn and colleagues that down-regulation of NEDD9 is part of a signature for breast cancer metastasis (20) may reflect the fact that NEDD9 is required at early stages in the tumor process but down-regulated after metastasis. Indeed, MMTV-PyVmT;Nedd9 À/À mammary tumor cells lines are less migratory than MMTV-PyVmT;Nedd9
+/+ cells, in agreement with our earlier observations that NEDD9 positively regulates cell migration and matrix metalloproteinase expression in transformed breast adenocarcinoma cells (12) but in opposition to the report that NEDD9 negatively regulates migration in normal mammary epithelial cells (19) . Alternatively, the different findings may reflect a distinct feature of the TGF-h model employed in the Minn and colleagues study. NEDD9 directly binds and influences the function of TGF-h effectors including SMAD3 (45) and other SMADs (46), making it plausible that NEDD9 might act differently in a TGF-h-driven tumor. Epithelial-tomesenchymal transition is an important consequence of increased TGF-h signaling in tumor metastasis. In support of the present study, we have examined several hallmarks of TGF-h-induced epithelial-to-mesenchymal transition in Nedd9 À/À tumors and tumor-derived cell lines, including up-regulation of vimentin and down-regulation of E-cadherin. No significant differences were detected in the MMTV-PyVmT model. 9 Finally, the difference between our data and those reported by Minn and colleagues may reflect a difference observed at the mRNA level that does not affect NEDD9 protein levels, as we and others have shown that NEDD9 undergoes significant post-translational regulation during cell division and cell death (9, 47) . More study of these issues is required.
Interestingly, our data indicate that continued expression of the NEDD9 paralogue p130
Cas /BCAR1 is unable to compensate for Nedd9-null status, although transgenic overexpression of p130 Cas activates Src and AKT and promotes mammary tumor progression in a mouse model (48) . A possible explanation lies in the typically nondynamic expression level of p130
Cas under different growth conditions. In contrast, NEDD9 is strikingly up-regulated in highly proliferating cells (17) and may be required to support the proliferation of such cells. Levels of p130
Cas were constant in tumors derived from Nedd9 À/À and Nedd9 +/+ mice (Fig. 4) , suggesting that, even under strong selective conditions, upregulation of this protein was either non-tumor-promoting or impossible in a Nedd9 À/À background. Another possibility is that NEDD9 induces additional signaling pathways that are not influenced by p130 Cas , which contribute specifically to tumor growth. In interesting contrast, p130
Cas À/À status is embryonally lethal (day 11.5; ref. 49) , whereas Nedd9 À/À status is not associated with known prenatal defects, emphasizing the different requirements for signaling proteins in tumors versus normal development. Large-scale studies of the breast cancer and other cancer genomes have begun to unearth a large number of potential prooncogenic mutations targeting genes previously not known to be important for cancer. These genes are not identical in different cancer types or in a given type of cancer arising in different individuals. In parallel, systems biology studies of large biological networks (50) have suggested that activity of cancer signaling pathways can be enhanced by inappropriate activation of proteins acting at various points within a pathway and that such activation can arise not only from mutations but also from epigenetic, posttranscriptional, or post-translational events that alter the signaling landscape of a cell. Together, these findings suggest that proteins that broadly influence pathway activation status may have important actions in conditioning cancer initiation and progression. Because NEDD9 is not only coupled to the cell adhesion and migration machinery (9, 32) but also contributes to normal mitotic progression (51) and mediates proliferative and survival signaling (47), we believe it is likely that the dynamic up-regulation of NEDD9 may represent convenient means for cancer signaling networks to coordinately activate multiple pathways useful for tumor growth.
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